Market for Anticoagulants Evolving Quickly as Generics and New-Generation Drugs Squeeze Incumbents
Despite Competitive Threats, Growth Prospects Continue to Lure Players According to Greystone Research Associates
(Amherst, NH) – The market for anticoagulants is currently more competitive than at any other time in its history.
Conditions that require anticoagulation therapy are overwhelmingly afflictions of the aging, with the leading
prescribing diagnosis being nonvalvular atrial fibrillation (AF). AF increases the risk of stroke. The degree of
increase can be substantial, depending on the presence of additional risk factors (such as high blood pressure). Legacy
treatments for coagulation illnesses include Coumadin and heparin.
Recently, new oral anticoagulant treatments that directly inhibit thrombin or Factor Xa . These treatments have had
significant commercial success despite suffering from a method for clinically necessary reversibility. Work with
proteins that could further expand the market by the end of the decade has the potential to place additional pressure on
established drugs.
The global market for anticoagulants is significant. Approximately 350,000 hospitalizations, 5.0 million office visits,
276,000 ED visits, and 234,000 OPD are attributable to AF annually within the U.S. alone. Total annual costs for
treatment of AF were estimated at $6.65 billion, including $2.93 billion (44%) for hospitalizations with a principal
discharge diagnosis of AF, $1.95 billion (29%) for the incremental inpatient cost of AF as a comorbid diagnosis, $1.53
billion (23%) for outpatient treatment of AF, and $235 million (4%) for prescription drugs.
These market survey findings are detailed in a new and comprehensive report researched and written by Greystone Research
Associates. The Evolving Market for Anticoagulants analyzes the global market for antocoagulants, providing assessments of demand drivers, development factors, market
considerations, strategic and economic factors, and profiles of market sector participants.
More information is available at http://www.greystoneassociates.org
ENDS